BridgeBio Pharma, Inc.
NASDAQ:BBIO
26.83 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 375.935 | 376.689 | 393.772 | 356.082 | 363.773 | 436.086 | 91.995 |
| Short Term Investments
| 58.949 | 95.233 | 442.891 | 251.011 | 182.22 | 0 | 0 |
| Cash and Short Term Investments
| 434.884 | 428.269 | 787.515 | 607.093 | 577.137 | 436.086 | 91.995 |
| Net Receivables
| 1.751 | 17.079 | 19.749 | 0 | 0 | 0 | 0 |
| Inventory
| 16.653 | 37.93 | -68.897 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 24.305 | 21.922 | 101.343 | 35.731 | 22.629 | 2.05 | 0.889 |
| Total Current Assets
| 477.593 | 505.2 | 839.71 | 642.824 | 599.766 | 445.223 | 97.131 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 19.843 | 25.247 | 45.973 | 36.833 | 5.625 | 1.575 | 0.44 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 26.319 | 28.712 | 44.934 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 26.319 | 28.712 | 44.934 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 3.744 | 43.653 | 49.148 | 2.6 | 31.144 | 17.05 | 0.381 |
| Tax Assets
| -3.744 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 22.625 | 20.224 | 33.027 | 21.331 | -4.856 | 1.093 | 0.092 |
| Total Non-Current Assets
| 68.787 | 117.836 | 173.082 | 60.764 | 31.913 | 19.718 | 0.913 |
| Total Assets
| 546.38 | 623.036 | 1,012.792 | 703.588 | 631.679 | 464.941 | 98.044 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 10.655 | 11.558 | 11.884 | 8.945 | 8.852 | 13.509 | 1.885 |
| Short Term Debt
| 4.128 | 3.675 | 4.938 | 1.458 | 8 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 6.096 | 8.156 | 0 | 75.9 | 31.455 | 0 | 0 |
| Other Current Liabilities
| 122.965 | 94.364 | 113.309 | 5.55 | 4.078 | 19.068 | 6.665 |
| Total Current Liabilities
| 143.844 | 117.753 | 130.131 | 91.853 | 52.385 | 32.577 | 8.55 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 1,735.71 | 1,723.564 | 1,726.171 | 494.329 | 99.791 | 54.507 | 143.867 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 9.361 | 26.643 | 22.069 | 9.52 | 3.527 | 479.36 | 0.312 |
| Total Non-Current Liabilities
| 1,745.071 | 1,750.207 | 1,748.24 | 503.849 | 103.318 | 533.867 | 144.179 |
| Total Liabilities
| 1,888.915 | 1,867.96 | 1,878.371 | 595.702 | 155.703 | 566.444 | 152.729 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 2.243 | 0.122 | 0.833 |
| Common Stock
| 0.181 | 0.157 | 0.154 | 0.125 | 0.124 | 6.594 | 3.411 |
| Retained Earnings
| -2,560.501 | -1,918.149 | -1,436.966 | -888.755 | -440.031 | -170.58 | -61.427 |
| Accumulated Other Comprehensive Income/Loss
| 0.031 | -0.328 | -0.132 | 0.192 | 0.254 | -0.231 | -0.027 |
| Other Total Stockholders Equity
| 1,206.032 | 663.703 | 566.53 | 946.344 | 845.864 | 0.109 | -0.806 |
| Total Shareholders Equity
| -1,354.257 | -1,254.617 | -870.414 | 57.906 | 408.454 | -163.986 | -58.016 |
| Total Equity
| -1,342.535 | -1,244.924 | -865.579 | 107.886 | 475.976 | -101.503 | -54.685 |
| Total Liabilities & Shareholders Equity
| 546.38 | 623.036 | 1,012.792 | 703.588 | 631.679 | 464.941 | 98.044 |